The UK and US have finalized a major bilateral deal that will keep no duties on UK medicine exports entering the American market.
The Terms of the Accord
As part of the deal, the UK has pledged to increase spending on drugs through the National Health Service (NHS). This move secures that import taxes on these key goods will remain at zero for a period of three years.
This agreement is in response to recent threats to significantly raise import taxes on patented pharmaceutical imports, with potential rates floated reaching double the cost.
"This deal between the Britain reinforces the global environment for cutting-edge drugs and establishes long-overdue balance to American-British pharmaceutical trade," a statement declared.
Commercial Significance
Drugs are one of the UK's biggest exports to the United States, which is clearly the primary market for leading British pharmaceutical firms.
Statistics show that in the one-year period prior to the third quarter, the UK sold pharmaceutical products valued at over eleven billion pounds to the US. This figure represented nearly one-fifth of British export trade in that span.
"This guarantee secures jobs, increases investment and facilitates the UK to establish itself as a global hub for biotech and pharma," the Business and Trade Secretary commented.
Key NHS Changes
The pact involves several specific changes from the UK:
- Revised Affordability Limit: The UK will increase the affordability limit at which it considers new medicines to be unaffordable by 25%.
- Increased NHS Spending: There is a goal to increase overall public funding on medicines from 0.3 percent of GDP to 0.6% over the coming ten years.
- Payback Limit: The amount pharmaceutical firms must refund to the NHS to prevent overspending will be limited at 15%. Previously, rebates exceeded twenty percent.
Industry Background
This agreement takes place against a long-running dispute between the drug companies and the UK government over medicine costs and regulatory access.
These tensions were exacerbated by assertions that US customers were paying several times more for the identical medicines than patients in the UK and Europe.
In recent months, several major drug company projects in the UK have been halted or cancelled, while major investments have been pledged toward US facilities.
One official acknowledged that the NHS had to invest a greater share on drugs, noting that its expenditure on drugs had declined as a percentage of its resources over the last ten years.
